Molecular Correlates of Long-Term Response to Bevacizumab in Glioblastoma.

ABSTRACT:

Purpose

The use of bevacizumab in glioblastoma has been associated with increased progression-free survival and improvement in symptoms and quality of life. There are no clinical indicators on how to choose patients who would benefit the most from this agent. We aim to describe molecular markers in patients with glioblastoma who may benefit from treatment.

Methods

We analyzed glioblastoma tumor samples that underwent comprehensive molecular profiling analysis at Caris Life Sciences.

Results

The data set consisted of 3,106 glioblastoma tumor samples, of which 571 were from patients treated with bevacizumab. The majority were males (65%) and older than 60 years. Median survival was 17.5 months in patients receiving bevacizumab. In patients who were treated with bevacizu

SUBMITTER: Villano JL 

PROVIDER: S-EPMC12539333 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature